Daily Respiratory Research Analysis
Analyzed 105 papers and selected 3 impactful papers.
Summary
Three studies stand out today: a phase 3 RCT shows tezepelumab produces early and sustained improvements in olfaction for uncontrolled CRSwNP; a systematic review clarifies best practices to convert noninvasive SpO2/FiO2 to PaO2/FiO2 in critical illness; and a nationwide prospective cohort defines seven Omicron-era ICU phenotypes with distinct outcomes, supporting phenotype-driven care.
Research Themes
- Biologic therapy improves upper airway function in CRSwNP
- Noninvasive oxygenation metrics for ICU respiratory failure
- Phenotype-driven management in Omicron-era critical COVID-19
Selected Articles
1. Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT).
In a phase 3, 52-week randomized trial of 408 adults with uncontrolled CRSwNP, tezepelumab significantly improved multiple olfactory endpoints versus placebo as early as day 7, with sustained benefits through week 52. The prevalence of anosmia was markedly lower with tezepelumab at weeks 4 and 52.
Impact: This trial provides robust, clinically meaningful evidence that TSLP blockade restores olfaction rapidly and durably in CRSwNP, a critical unmet need with safety and quality-of-life implications.
Clinical Implications: Tezepelumab could be prioritized for CRSwNP patients with prominent smell loss, with expectations of early benefit. Objective tests (UPSIT) and patient-reported outcomes support monitoring response.
Key Findings
- Tezepelumab improved NPSD smell scores at week 4 and week 52 (LSM differences −0.36 and −1.01; nominal p<0.0001).
- UPSIT increased by 6.03 at week 4 and 9.50 at week 52 versus placebo (nominal p<0.0001).
- Between-group differences appeared by day 7 in daily smell scores; anosmia prevalence was substantially lower at weeks 4 and 52 with tezepelumab.
Methodological Strengths
- Phase 3, multicenter randomized design with 52-week follow-up
- Use of objective (UPSIT) and validated patient-reported outcomes, with prespecified subgroup analyses
Limitations
- Reported p-values are nominal; multiplicity control details are not provided in the abstract
- Generalizability limited to uncontrolled CRSwNP; effects on broader CRS phenotypes are unknown
Future Directions: Head-to-head comparisons with other biologics, durability beyond 52 weeks, and biomarker-guided selection (e.g., TSLP-driven endotypes) should be evaluated.
BACKGROUND: Loss of smell is a principal symptom of chronic rhinosinusitis with nasal polyps (CRSwNP), affecting HRQoL and posing a safety hazard. METHODS: WAYPOINT (NCT04851964), a phase 3, multicenter trial in adults with uncontrolled CRSwNP, randomized patients 1:1 to receive tezepelumab 210 mg or placebo subcutaneously every 4 weeks for 52 weeks. Changes from baseline in biweekly mean Nasal Polyposis Symptom Diary (NPSD) loss of smell item, University of Pennsylvania Smell Identification Test (UPSIT), and 22-item Sino-Nasal Outcome Test (SNOT-22) loss of smell/taste item scores, as well as anosmia (UPSIT score ≤18) prevalence, were assessed over 52 weeks. RESULTS: Among 408 patients (tezepelumab [n = 203]; placebo [n = 205]), significant improvements with tezepelumab versus placebo in NPSD loss of smell item, UPSIT, and SNOT-22 loss of smell/taste item scores were seen at week 4 (least-squares mean [LSM] treatment difference [95% CI]: -0.36 [-0.46, -0.27]; 6.03 [4.72, 7.34]; and -1.01 [-1.22, -0.80], respectively) and week 52 (-1.01 [-1.18, -0.83]; 9.50 [7.84, 11.16]; and -1.90 [-2.20, -1.61]); all nominal p < 0.0001. Between-treatment differences in daily NPSD loss of smell item score were evident from day 7 (LSM treatment difference: -0.08 [95% CI: -0.15, -0.02]; nominal p < 0.01). Improvements in NPSD loss of smell, UPSIT, and SNOT-22 loss of smell/taste item scores were observed across multiple prespecified subgroups. Anosmia prevalence was lower with tezepelumab than placebo at week 4 (43.0% [n/N = 64/149] vs. 80.3% [n/N = 106/132]) and week 52 (31.5% [n/N = 55/149] vs. 75.8% [n/N = 100/132]). CONCLUSIONS: Tezepelumab provides early and sustained improvements in the sense of smell among patients with uncontrolled CRSwNP.
2. Approaches to Converting Spo2/Fio2 Ratio to Pao2/Fio2 Ratio for Assessment of Respiratory Failure in Critically Ill Patients: A Systematic Review.
Across 45 observational studies, SF and PF ratios correlate strongly, though accuracy degrades at SpO2 ≥97%. The authors prioritize four conversion equations based on usability and evidence, with simple linear models being most practical at the bedside and SF showing prognostic performance comparable to PF.
Impact: Provides synthesis and practical guidance for noninvasive oxygenation assessment, enabling broader application where arterial blood gases are unavailable or delayed.
Clinical Implications: Clinicians can use SF-based linear conversion to estimate PF at the bedside, avoiding reliance on arterial lines, while exercising caution when SpO2 is ≥97%. SF may be incorporated into severity scores and ARDS assessments.
Key Findings
- Strong correlation between SpO2/FiO2 and PaO2/FiO2 across 45 studies.
- Accuracy of SF-to-PF conversion decreases when SpO2 ≥97%.
- Four prioritized equations (including a simple linear equation) balance ease of use and performance; SF had prognostic value comparable to PF.
Methodological Strengths
- Comprehensive search across multiple databases with risk-of-bias assessment (QUADAS-2)
- Large cumulative measurement base (up to 141,000) and practical prioritization of equations
Limitations
- All included studies were observational with heterogeneity in patient populations and measurement protocols
- No single universally optimal equation; diminished accuracy at high SpO2 limits generalizability
Future Directions: Prospective validation of prioritized equations across ICU subpopulations and integration into electronic decision support with saturation-aware safeguards.
OBJECTIVE: The Pao2/Fio2 (PF) ratio is widely used as an assessment of respiratory failure in guiding ventilation strategies and prognostication in critically ill patients. However, given that it mandates invasive arterial access, the Spo2/Fio2 (SF) ratio has been suggested as a noninvasive and readily accessible alternative. What are the best ways to convert SF and PF ratios in critically ill patients, in terms of their diagnostic/prognostic accuracy and clinical utility? DATA SOURCES: We comprehensively searched databases (MEDLINE, Embase, Web of Science, Cochrane library) to identify relevant studies. STUDY SELECTION: Any observational studies that compared the SF to PF ratio in critically ill patients. We assessed individual study risk of bias (ROB) using the revised QUADAS II tool. DATA EXTRACTION: We included 45 observational studies, ranging from 61 to 141,000 measurements. DATA SYNTHESIS: SF to PF imputation was less accurate when the Spo2 was equal to or greater than 97%. Otherwise, all studies were able to establish strong correlational relationships between SF and PF ratios, but there was no clear best equation. Based on ease of use, size, generalizability and methodology, we were able to prioritize four equations (one linear, one logarithmic linear, and two nonlinear). All four equations showed strong correlation between SF and PF ratios, with the linear equation being easiest to apply. The SF ratio also correlated well with clinical outcomes when compared with the PF ratio, both as an individual value and as part of a comprehensive score, with more discriminating performance in some cases. CONCLUSIONS: SF and PF ratios demonstrate good correlation, and may have similar prognostic value. Although there is no clear optimal method to convert SF to PF ratios, linear equations show acceptable correlation and are most easily applied at the bedside.
3. Clinical Phenotypes of Critically Ill Patients with COVID-19 Infected with Omicron: A Nationwide Prospective Cohort Study.
In 777 Omicron-infected ICU patients across 39 centers, seven phenotypes with distinct comorbidities, management, and outcomes were identified using unsupervised clustering. Day-28 mortality ranged from 13.1% (younger, isolated chronic respiratory failure) to 41.1% (multiorgan failure), supporting phenotype-informed care pathways and trial stratification.
Impact: Defines actionable phenotypes in Omicron-era critical COVID-19, enabling targeted therapies and resource allocation and informing design of future trials.
Clinical Implications: ICU teams can tailor organ support and immunomodulatory therapies based on phenotype (e.g., high-risk multiorgan failure or transplant clusters), and use phenotypes for prognostication and enrollment stratification.
Key Findings
- Seven distinct Omicron ICU phenotypes were identified using SOM and independent validation (ClinTrajan).
- Day-28 mortality varied widely: 13.1% (cluster 3) to 41.1% (cluster 6).
- Therapeutic intensity differed by cluster (e.g., more invasive ventilation and RRT in clusters 5 and 7; frequent dexamethasone/tocilizumab in cluster 4).
Methodological Strengths
- Prospective, multicenter design across 39 ICUs with substantial sample size (n=777)
- Use of two independent unsupervised clustering approaches for validation
Limitations
- Observational design with potential residual confounding and treatment-by-indication bias
- Temporal variability (2021–2024) and country-specific practice patterns may limit generalizability
Future Directions: Prospective interventional trials should stratify by phenotype to test tailored therapies; external validation and dynamic phenotyping with biomarkers are warranted.
INTRODUCTION: The clinical presentation of critically ill patients with coronavirus disease 2019 (COVID-19) has evolved significantly with the emergence of the Omicron variant. Current intensive care unit (ICU) admissions involve patients with diverse comorbidities and immune statuses, highlighting the need to redefine homogeneous phenotypic subgroups within this population. This study aimed to characterize distinct clinical phenotypes among critically ill patients with COVID-19 and acute respiratory failure. METHODS: This multicenter prospective substudy of the SEVARVIR cohort included adult patients from 39 French ICUs between December 2021 and October 2024 with acute respiratory failure and infected with the Omicron variant. Clustering analysis was conducted using Kohonen's self-organizing maps (SOMs) and validated with ClinTrajan, two unsupervised clustering methods, to identify homogeneous patient phenotypes. RESULTS: During the study period, 777 patients with Omicron infection were included, and 7 distinct clinical clusters were identified. Clusters 1 and 2 included patients with metabolic and cardiovascular comorbidities. Cluster 3 featured younger, mildly ill patients with isolated chronic respiratory failure, while cluster 4 comprised older male patients with isolated respiratory failure. Cluster 5 included patients with isolated hematologic malignancies, cluster 6 patients with multiorgan failure, and cluster 7 organ transplant recipients, with high severity scores and impaired renal function. ICU management varied substantially across clusters. Patients in clusters 5 and 7 had the highest requirements for organ support, with frequent use of invasive mechanical ventilation, vasopressors (cluster 6), and renal replacement therapy (cluster 7). Dexamethasone and tocilizumab were most commonly prescribed in cluster 4 (91.3% and 30.2%, respectively). Mortality at day 28 varied significantly across clusters, ranging from 13.1% in cluster 3 to 41.1% in cluster 6. CONCLUSIONS: This clustering analysis highlights, for the first time, the clinical heterogeneity of critically ill patients infected with Omicron, identifying seven distinct clusters with varying clinical presentations, management strategies and outcomes. These findings underscore the relevance of a phenotype-driven approach to support personalized treatment strategies and guide future clinical trials. TRIAL REGISTRATION: Clinicaltrials.gov, NCT05162508. A Graphical Abstract is available for this article.